Table 1

Patient characteristics

Controls (n = 20)

TREACH (n = 38)

FLARE (n = 37)


Female gender, n (%)

10 (50)

25 (65.8)

25 (67.6)


Age in years, mean (SD)

31.8 (9.7)

53.3 (13.98)a

53.7 (13.40)a


Disease duration in months, median (range)

-

5.4 (2-12)

73.0 (0-414)b


Presence of joint erosions, n (%)

-

10 (26.3)

20 (54.1)c


Anti-CCP positive, n (%)

-

30 (78.9)

24 (85.7)d


Rheumatoid factor (IgM) positive, n (%)

-

31 (81.6)

27 (73.0)


DAS44 at baseline, mean (SD)

-

3.05 (0.92)

3.57 (0.95)c


HAQ-DI at baseline, mean (SD)

-

-

1.43 (0.62)


Use of NSAID, n (%)

-

25 (67.6)

19 (51.4)


Use of methotrexate, n (%)

-

-

22 (59.5)


Use of hydroxychloroquine, n (%)

-

-

11 (29.7)


Use of sulfasalazine, n (%)

-

-

5 (13.5)


Number of DMARDs, median (range)

-

-

1 (0-3)e


Use of anti-TNF-α therapy, n (%)

-

-

5 (13.5)


DAS44, Disease Activity Score, 44 joints; HAQ-DI, Health Assessment Questionnaire Disability Index. aP < 0.001 as compared with healthy controls; bP < 0.001 as compared with tREACH patients; cP < 0.05; danti-CCP was not routinely analyzed; percentage is based on 28 patients with known anti-CCP status; eSeven patients were not using any DMARD at the time of assessment.

Quax et al. Arthritis Research & Therapy 2012 14:R195   doi:10.1186/ar4029

Open Data